PBIO - Pressure BioSciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
3.90
-0.10 (-2.50%)
As of 9:42AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.00
Open3.83
Bid0.00 x 0
Ask0.00 x 0
Day's Range3.83 - 3.90
52 Week Range0.70 - 9.30
Volume834
Avg. Volume1,580
Market Cap5.335M
Beta1.54
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research4 months ago

    PBIO: Enters Biopharmaceutical Quality Control Market

    This enhanced software was through the collaboration between PBIO and its biopharmaceutical company customers. The enhanced software makes the 2320EXT one of the few Good Manufacturing Practices (GMP) compliant, computer-controlled, sample preparation systems available in the worldwide life sciences market today. The 2320EXT is primarily used in the sample preparation (tissues, cells, proteins, etc.) for analysis.

  • Pressure BioSciences, Inc. :PBIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube5 months ago

    Pressure BioSciences, Inc. :PBIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis Pressure BioSciences, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Pressure BioSciences, Inc. – Waters Corporation, Bruker Corporation, General Electric Company, Harvard Bioscience, Inc., Thermo Fisher Scientific Inc. and PerkinElmer, Inc. (WAT-US, BRKR-US, GE-US, HBIO-US, TMO-US and PKI-US) ... Read more (Read more...)

  • Zacks Small Cap Research5 months ago

    PBIO: Revenue Expected to Continue to Grow

    Total revenue for 3Q17 was $646,061, compared to $535,334 in 3Q16, an increase of $110,727 (21%). This increase was primarily attributable to increases in both instrument and consumable sales. Total revenue included product & services revenue and grant revenue.

  • Pressure BioSciences, Inc. :PBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
    Capital Cube8 months ago

    Pressure BioSciences, Inc. :PBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017

    Categories: Yahoo FinanceGet free summary analysis Pressure BioSciences, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Pressure BioSciences, Inc. – Waters Corporation, Bruker Corporation, General Electric Company, Harvard Bioscience, Inc., Thermo Fisher Scientific Inc. and PerkinElmer, Inc. (WAT-US, BRKR-US, GE-US, HBIO-US, TMO-US and PKI-US) ... Read more (Read more...)

  • Zacks Small Cap Research11 months ago

    PBIO: Significant Revenue Growth Expected for 2017 and Beyond

    Total revenue for the first quarter 2017 was $0.55 million, as compared to total revenue of $0.51 million for the first quarter 2016, an increase of 8.0%. This increase was primarily attributable to an increase of 19% in the sale of instrument systems, from $332,016 in Q1 2016 to $396,095 in the same quarter of 2017. This decrease was primarily due to reduced R&D expenses combined with increased sales of product and services.

  • Pressure BioSciences, Inc. :PBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017
    Capital Cube11 months ago

    Pressure BioSciences, Inc. :PBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017

    Categories: Yahoo FinanceGet free summary analysis Pressure BioSciences, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Pressure BioSciences, Inc. – Waters Corporation, MOCON, Inc., PerkinElmer, Inc., General Electric Company, Harvard Bioscience, Inc., Thermo Fisher Scientific Inc. and Bruker Corporation (WAT-US, MOCO-US, PKI-US, GE-US, HBIO-US, ... Read more (Read more...)